Perspective Therapeutics Raises $175M and Reports 76% Progression-Free Rate
Perspective Therapeutics sold 39.57 million shares at $3.78, raising about $175 million to fund clinical programs, expand manufacturing and pursue acquisitions. Its VMT-α-NET neuroendocrine tumor trial achieved 76% progression-free rate and 39% response in Cohort 2, prompting H.C. Wainwright to raise its price target to $12.
1. Offering Details
On February 2, the company sold 39.57 million shares at $3.78 each in an underwritten offering, generating approximately $175 million in gross proceeds. Net funds are earmarked to advance clinical development, upgrade manufacturing facilities, bolster working capital and potentially acquire or license complementary technologies.
2. Trial Progress and Data
The lead candidate, VMT-α-NET for neuroendocrine tumors, continues strong patient recruitment and tolerability, with mid-year updates expected. ASCO GU 2026 results showed a 76% progression-free rate and 39% response in Cohort 2, and the company is now evaluating higher doses in Cohort 3 to enhance efficacy.
3. Analyst Upgrade and Competitive Edge
H.C. Wainwright raised its price target from $10 to $12, citing Perspective’s unopposed lead radioimmunotherapy following Sanofi’s exit from the SSTR2-targeted space. Management forecasts maturing clinical data across all programs in 2026, positioning the company as a frontrunner in targeted alpha-particle therapies.